# Peter W M Johnson

List of Publications by Year
in descending order



| 256 | 18,362 | 11651 70 | 13771 129 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 265 | 265 | 265 | 19238 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine, 2013, 369, 507-516. | 27.0 | 1,449 |
| 2 | Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2016, 374, 2419-2429. | 27.0 | 629 |
| 3 | Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2015, 372, 1598-1607. | 27.0 | 619 |
| 4 | Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ, The, 2020, 371, m3731. | 6.0 | 471 |
| 5 | Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet, The, 2013, 381, 1817-1826. | 13.7 | 450 |
| 6 | European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma. Journal of Clinical Oncology, 2000, 18, 317-317. | 1.6 | 448 |
| 7 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227. | 4.6 | 442 |
| 8 | Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Nonâ€“Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 1285-1295. | 1.6 | 388 |
| 9 | Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood, 2003, 101, 1045-1052. | 1.4 | 353 |
| 10 | Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood, 2015, 126, 739-745. | 1.4 | 349 |
| 11 | Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.. Journal of Clinical Oncology, 1995, 13, 140-147. | 1.6 | 319 |
| 12 | Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1824-1833. | 6.4 | 298 |
| 13 | Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood, 2010, 115, 5191-5201. | 1.4 | 292 |
| 14 | Clinical trials of antibody therapy. Trends in Immunology, 2000, 21, 403-410. | 7.5 | 277 |
| 15 | Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology, 2019, 37, 481-489. | 1.6 | 265 |
| 16 | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523. | 4.6 | 258 |
| 17 | First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 2008, 111, 5486-5495. | 1.4 | 247 |
| 18 | Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 2002, 99, 2562-2568. | 1.4 | 237 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Validation and comparison of two multiplex technologies, LuminexÂ® and Mesoscale Discovery, for human cytokine profiling. Journal of Immunological Methods, 2009, 340, 55-64. | 1.4 | 237 |
| 20 | Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 2010, 95, 135-143. | 3.5 | 228 |
| 21 | Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood, 2011, 118, 2530-2540. | 1.4 | 226 |
| 22 | Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.. Journal of Clinical Oncology, 1994, 12, 1177-1184. | 1.6 | 218 |
| 23 | Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ, The, 2021, 374, n2244. | 6.0 | 208 |
| 24 | Mcl-1. International Journal of Biochemistry and Cell Biology, 2005, 37, 267-271. | 2.8 | 203 |
| 25 | Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology, 2013, 31, 565-572. | 1.6 | 198 |
| 26 | Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 649-662. | 10.7 | 187 |
| 27 | Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. Journal of Clinical Oncology, 2019, 37, 202-212. | 1.6 | 187 |
| 28 | The mechanisms of action of rituximab in the elimination of tumor cells. Seminars in Oncology, 2003, 30, 3-8. | 2.2 | 186 |
| 29 | High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. Journal of Clinical Oncology, 2000, 18, 527-527. | 1.6 | 168 |
| 30 | Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 2009, 27, 5390-5396. | 1.6 | 164 |
| 31 | Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity. Journal of Clinical Oncology, 2006, 24, 2105-2112. | 1.6 | 163 |
| 32 | Mechanism of action of rituximab. Anti-Cancer Drugs, 2002, 13, S3-S10. | 1.4 | 161 |
| 33 | Primary Mediastinal B-Cell Lymphoma. American Journal of Pathology, 2003, 162, 243-253. | 3.8 | 160 |
| 34 | Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics, 2016, 48, 183-188. | 21.4 | 160 |
| 35 | Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group. Journal of Clinical Oncology, 2005, 23, 142-153. | 1.6 | 152 |
| 36 | Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18587-18592. | 7.1 | 151 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The molecular detection of circulating tumour cells. British Journal of Cancer, 1995, 72, 268-276. | 6.4 | 149 |
| 38 | [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Journal of Clinical Oncology, 2014, 32, 1769-1775. | 1.6 | 149 |
| 39 | A MALT lymphoma prognostic index. Blood, 2017, 130, 1409-1417. | 1.4 | 149 |
| 40 | PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, 2016, 127, 1531-1538. | 1.4 | 143 |
| 41 | Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of Clinical Oncology, 2017, 35, 1905-1912. | 1.6 | 143 |
| 42 | Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology, 2013, 31, 573-583. | 1.6 | 142 |
| 43 | Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood, 2015, 126, 950-956. | 1.4 | 138 |
| 44 | Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524. | 7.4 | 136 |
| 45 | Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies. Cancer Cell, 2015, 27, 138-148. | 16.8 | 135 |
| 46 | Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene, 2004, 23, 4818-4827. | 5.9 | 133 |
| 47 | Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Journal of Clinical Oncology, 2005, 23, 9208-9218. | 1.6 | 130 |
| 48 | Prediction of singleâ€nucleotide substitutions that result in exon skipping: identification of a splicing silencer inBRCA1exon 6. Human Mutation, 2011, 32, 436-444. | 2.5 | 120 |
| 49 | Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling. Journal of Biological Chemistry, 2008, 283, 16971-16984. | 3.4 | 118 |
| 50 | Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8ÂT Cell Effector Function. Immunity, 2018, 49, 958-970.e7. | 14.3 | 114 |
| 51 | Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research, 2019, 25, 7331-7339. | 7.0 | 110 |
| 52 | DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14646-14652. | 7.1 | 109 |
| 53 | Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood, 2020, 135, 680-688. | 1.4 | 109 |
| 54 | A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.. Journal of Clinical Oncology, 1994, 12, 1427-1435. | 1.6 | 108 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Antagonistic Human FcÎ³RIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy InÂVivo. Cancer Cell, 2015, 27, 473-488. | 16.8 | 108 |
| 56 | Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood, 2007, 109, 4810-4815. | 1.4 | 103 |
| 57 | A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology, 2000, 109, 81-88. | 2.5 | 101 |
| 58 | S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Research and Treatment, 2011, 127, 109-119. | 2.5 | 94 |
| 59 | Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma.. Journal of Clinical Oncology, 1994, 12, 798-805. | 1.6 | 92 |
| 60 | Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia, 2018, 32, 1261-1265. | 7.2 | 87 |
| 61 | Rituximab: mechanisms and applications. British Journal of Cancer, 2001, 85, 1619-1623. | 6.4 | 86 |
| 62 | CD40 Induces Interleukin-6 Gene Transcription in Dendritic Cells. Journal of Biological Chemistry, 2002, 277, 17125-17138. | 3.4 | 86 |
| 63 | Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. British Journal of Cancer, 1996, 74, 463-467. | 6.4 | 82 |
| 64 | Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. British Journal of Cancer, 2008, 99, 689-694. | 6.4 | 82 |
| 65 | Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cellâ€“dependent immunity to B-cell lymphoma. Blood, 2003, 102, 1449-1457. | 1.4 | 81 |
| 66 | Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. Clinical Cancer Research, 2015, 21, 1321-1328. | 7.0 | 81 |
| 67 | Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood, 2009, 113, 1412-1421. | 1.4 | 79 |
| 68 | Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519). Journal of Clinical Oncology, 2010, 28, 3352-3359. | 1.6 | 79 |
| 69 | Primary mediastinal large B-cell lymphoma. Critical Reviews in Oncology/Hematology, 2017, 113, 318-327. | 4.4 | 77 |
| 70 | IL-4 enhances expression and function of surface IgM in CLL cells. Blood, 2016, 127, 3015-3025. | 1.4 | 76 |
| 71 | Pharmacological inhibitors of NF-ÎºB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene, 2007, 26, 1166-1177. | 5.9 | 74 |
| 72 | The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biology and Therapy, 2010, 10, 728-735. | 3.4 | 72 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. British Journal of Cancer, 1999, 79, 509-514. | 6.4 | 71 |
| 74 | Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood, 2021, 137, 637-645. | 1.4 | 69 |
| 75 | Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochemical Pharmacology, 2008, 76, 463-475. | 4.4 | 67 |
| 76 | The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208. | 3.5 | 67 |
| 77 | Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia, 2020, 34, 1329-1341. | 7.2 | 66 |
| 78 | Hdm2 Recruits a Hypoxia-Sensitive Corepressor to Negatively Regulate p53-Dependent Transcription. Current Biology, 2003, 13, 1234-1239. | 3.9 | 65 |
| 79 | Primary Mediastinal B-Cell Lymphoma. Hematology American Society of Hematology Education Program, 2008, 2008, 349-358. | 2.5 | 65 |
| 80 | Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematology,the, 2021, 8, e542-e544. | 4.6 | 64 |
| 81 | The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. Oncogene, 2003, 22, 4973-4982. | 5.9 | 63 |
| 82 | Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2010, 151, 346-353. | 2.5 | 63 |
| 83 | Establishment of a UK-wide network to facilitate the acquisition of quality assured FDGâ€“PET data for clinical trials in lymphoma. Annals of Oncology, 2011, 22, 739-745. | 1.2 | 63 |
| 84 | Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 1328-1337. | 10.7 | 62 |
| 85 | Primary mediastinal large B-cell lymphoma. Critical Reviews in Oncology/Hematology, 2008, 68, 256-263. | 4.4 | 60 |
| 86 | FcÎ³ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization. Journal of Immunology, 2014, 193, 1828-1835. | 0.8 | 56 |
| 87 | The prognosis of MYC translocation positive diffuse large Bâ€cell lymphoma depends on the second hit. Journal of Pathology: Clinical Research, 2015, 1, 125-133. | 3.0 | 56 |
| 88 | The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. British Journal of Haematology, 2006, 134, 385-390. | 2.5 | 55 |
| 89 | The Effects of Malignant Transformation on Susceptibility of Human Urothelial Cells to CD40-Mediated Apoptosis. Journal of the National Cancer Institute, 2002, 94, 1381-1395. | 6.3 | 52 |
| 90 | Optimising antiâ€tumour CD8 Tâ€cell responses using combinations of immunomodulatory antibodies. European Journal of Immunology, 2008, 38, 2499-2511. | 2.9 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell, 2017, 32, 777-791.e6. | 16.8 | 52 |
| 92 | The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2313-2324. | 7.0 | 51 |
| 93 | Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 2022, 3, 552-564. | 13.2 | 51 |
| 94 | Use of a biosimilar granulocyte colonyâ€stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. British Journal of Haematology, 2013, 162, 107-111. | 2.5 | 50 |
| 95 | CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematology,the, 2018, 5, e190-e200. | 4.6 | 50 |
| 96 | Differential regulation of cell survival by CD40. Apoptosis: an International Journal on Programmed Cell Death, 2003, 8, 45-53. | 4.9 | 48 |
| 97 | Differential Impact of CD27 and 4-1BB Costimulation on Effector and Memory CD8 T Cell Generation following Peptide Immunization. Journal of Immunology, 2014, 193, 244-251. | 0.8 | 46 |
| 98 | Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. Blood, 2020, 136, 45-46. | 1.4 | 45 |
| 99 | Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Investigational New Drugs, 2006, 24, 223-231. | 2.6 | 42 |
| 100 | FcÎ³RÎ™Î™B controls the potency of agonistic anti-TNFR mAbs. Cancer Immunology, Immunotherapy, 2013, 62, 941-948. | 4.2 | 41 |
| 101 | Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells. Current Medicinal Chemistry, 2004, 11, 1031-1040. | 2.4 | 40 |
| 102 | Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Annals of Oncology, 1999, 10, 1349-1354. | 1.2 | 38 |
| 103 | Novel antibodies targeting immune regulatory checkpoints for cancer therapy. British Journal of Clinical Pharmacology, 2013, 76, 233-247. | 2.4 | 38 |
| 104 | Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (Râ€<scp>CHOP</scp>) in the management of primary mediastinal Bâ€cell lymphoma: a subgroup analysis of the <scp>UK NCRI</scp> Râ€<scp>CHOP</scp> 14 versus 21 trial. British Journal of Haematology, 2016, 175, 668-672. | 2.5 | 38 |
| 105 | Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica, 2017, 102, 1748-1757. | 3.5 | 38 |
| 106 | Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Scientific Reports, 2018, 8, 2278. | 3.3 | 38 |
| 107 | Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. Journal of Clinical Oncology, 2019, 37, 1732-1741. | 1.6 | 38 |
| 108 | The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. Lancet Oncology, The, 2021, 22, 66-73. | 10.7 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | The European Cancer Patientâ€™s Bill of Rights, update and implementation 2016. ESMO Open, 2016, 1, e000127. | 4.5 | 36 |
| 110 | Spontaneous clinical regression in chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 116, 341-345. | 2.5 | 34 |
| 111 | The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the EÂµ-TCL1 mouse model. Blood, 2015, 125, 4032-4041. | 1.4 | 34 |
| 112 | Expression of the inhibitory Fc gamma receptor <scp>IIB</scp> (<scp>FCGR</scp>2B, <scp>CD</scp>32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (<scp>SAKK</scp>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 2.5 | 34 |
| 113 | COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. European Journal of Cancer, 2022, 175, 1-10. | 2.8 | 34 |
| 114 | Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy, 2014, 6, 1187-1206. | 2.0 | 33 |
| 115 | KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood, 2021, 138, 370-381. | 1.4 | 33 |
| 116 | Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. Journal of Nuclear Medicine, 2018, 59, 1167-1169. | 5.0 | 32 |
| 117 | Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 42-49. | 0.8 | 31 |
| 118 | Thioflavin S (NSC71948) Interferes with Bcl-2-Associated Athanogene (BAG-1)-Mediated Protein-Protein Interactions. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 680-689. | 2.5 | 30 |
| 119 | All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 316-317. | 6.4 | 28 |
| 120 | EFFECTS OF INTERLEUKIN 6 ADMINISTRATION ON PLATELETS AND HAEMOPOIETIC PROGENITOR CELLS IN PERIPHERAL BLOOD. Cytokine, 1996, 8, 717-723. | 3.2 | 27 |
| 121 | <sup>18</sup>F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?. Journal of Nuclear Medicine, 2017, 58, 1539-1544. | 5.0 | 27 |
| 122 | The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica, 2016, 101, 235-240. | 3.5 | 24 |
| 123 | BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Advances, 2020, 4, 3316-3328. | 5.2 | 24 |
| 124 | How I treat advanced classical Hodgkin lymphoma. Blood, 2015, 125, 1717-1723. | 1.4 | 23 |
| 125 | Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Clinical Cancer Research, 2019, 25, 2503-2512. | 7.0 | 23 |
| 126 | Treatment of advanced-stage Hodgkin lymphoma. Seminars in Hematology, 2016, 53, 171-179. | 3.4 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood, 2018, 131, 1679-1688. | 1.4 | 22 |
| 128 | Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood, 2004, 103, 1485-1494. | 1.4 | 21 |
| 129 | The Use of Anti-CD40 mAb in Cancer. Current Topics in Microbiology and Immunology, 2014, 405, 165-207. | 1.1 | 21 |
| 130 | Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Research, 2007, 9, R46. | 5.0 | 20 |
| 131 | IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types. Hematological Oncology, 2015, 33, 29-32. | 1.7 | 20 |
| 132 | Prognostic models for primary mediastinal (thymic) Bâ€cell lymphoma derived from 18â€<scp>FDG PET</scp>/<scp>CT</scp> quantitative parameters in the International Extranodal Lymphoma Study Group (<scp>IELSG</scp>) 26 study. British Journal of Haematology, 2017, 178, 588-591. | 2.5 | 20 |
| 133 | A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.. Blood, 2006, 108, 425-425. | 1.4 | 20 |
| 134 | Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5<br>FDG-PET Scan after 3 Cycles ABVD. Blood, 2008, 112, 369-369. | 1.4 | 20 |
| 135 | A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425). Blood, 2015, 126, 812-812. | 1.4 | 20 |
| 136 | Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International, 2015, 2015, 1-9. | 1.9 | 19 |
| 137 | Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or â€˜Aggressive' Lymphoma.. Blood, 2009, 114, 584-584. | 1.4 | 19 |
| 138 | Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. British Journal of Haematology, 2006, 132, 743-746. | 2.5 | 18 |
| 139 | A stimulating new target for cancer immunotherapy. Lancet, The, 1999, 354, 1225-1227. | 13.7 | 17 |
| 140 | Short peptides derived from the BAGâ€1 Câ€terminus inhibit the interaction between BAGâ€1 and HSC70 and decrease breast cancer cell growth. FEBS Letters, 2009, 583, 3405-3411. | 2.8 | 17 |
| 141 | Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?. Hematology American Society of Hematology Education Program, 2016, 2016, 316-322. | 2.5 | 17 |
| 142 | Earlyâ€stage Hodgkin lymphoma in the modern era: simulation modelling to delineate longâ€term patient outcomes. British Journal of Haematology, 2018, 182, 212-221. | 2.5 | 17 |
| 143 | First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBodyÂ®-CD3Ã—CD20) in B-Cell Non-Hodgkin Lymphomas. Blood, 2019, 134, 758-758. | 1.4 | 17 |
| 144 | A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 784-784. | 1.4 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Identification of a novel human BCL-X promoter and exon. Oncogene, 2000, 19, 5534-5538. | 5.9 | 15 |
| 146 | Therapeutic potential of immunostimulatory monoclonal antibodies. Clinical Science, 2006, 111, 93-106. | 4.3 | 15 |
| 147 | Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. Translational Oncology, 2018, 11, 1147-1154. | 3.7 | 15 |
| 148 | Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. Blood Advances, 2020, 4, 203-206. | 5.2 | 15 |
| 149 | Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 328-337. | 1.5 | 14 |
| 150 | Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1334-1344. | 6.4 | 14 |
| 151 | Moving the goalposts while scoringâ€•the dilemma posed by new PET technologies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2696-2710. | 6.4 | 13 |
| 152 | Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Annals of Oncology, 2010, 21, 568-573. | 1.2 | 12 |
| 153 | Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5â€year results from a <scp>UK</scp> National Cancer Research Institute Lymphoma Group study. British Journal of Haematology, 2016, 173, 274-282. | 2.5 | 12 |
| 154 | BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia, 2020, 34, 640-644. | 7.2 | 12 |
| 155 | Targeted Radiotherapy in the Conditioning Prior to Haematopoietic Stem Cell Transplantation: Results of a Phase I Radiation Dose Escalation Study Using Yttrium-90-Labelled Anti-CD66 Monoclonal Antibody Demonstrating High BM Uptake of Radiation.. Blood, 2005, 106, 2189-2189. | 1.4 | 12 |
| 156 | Controversies in the Treatment of Classical Hodgkin Lymphoma. HemaSphere, 2018, 2, e149. | 2.7 | 11 |
| 157 | Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality. Laboratory Investigation, 2018, 98, 1084-1092. | 3.7 | 11 |
| 158 | Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1850-1859. | 1.3 | 11 |
| 159 | A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkinâ€™s lymphomas (NHL), multiple myeloma (MM) and solid tumor.. Journal of Clinical Oncology, 2016, 34, TPS2595-TPS2595. | 1.6 | 11 |
| 160 | Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.. Blood, 2007, 110, 1055-1055. | 1.4 | 11 |
| 161 | BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells. Oncology Reports, 2008, 19, 689-96. | 2.6 | 11 |
| 162 | Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma. Cancer Research, 2007, 67, 1335-1343. | 0.9 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Antibodyâ€“peptideâ€“MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunology, Immunotherapy, 2013, 62, 1093-1105. | 4.2 | 10 |
| 164 | Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial. Blood, 2019, 134, 354-354. | 1.4 | 10 |
| 165 | Management of early-stage Hodgkin lymphoma: is there still a role for radiation?. Hematology American Society of Hematology Education Program, 2013, 2013, 400-405. | 2.5 | 9 |
| 166 | Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. International Journal of Environmental Research and Public Health, 2020, 17, 1783. | 2.6 | 9 |
| 167 | Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2019, 134, 761-761. | 1.4 | 9 |
| 168 | The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. Blood, 2016, 128, 1746-1746. | 1.4 | 9 |
| 169 | A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2014, 32, TPS8615-TPS8615. | 1.6 | 9 |
| 170 | Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. Frontiers in Oncology, 2021, 11, 785635. | 2.8 | 9 |
| 171 | Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204). Blood, 2020, 136, 27-28. | 1.4 | 9 |
| 172 | Focal skeletal <scp>FDG</scp> uptake indicates poor prognosis in <scp>cHL</scp> regardless of extent and firstâ€line chemotherapy. British Journal of Haematology, 2019, 186, 431-439. | 2.5 | 8 |
| 173 | Prognostic indices in diffuse large Bâ€cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute Râ€CHOP 14 versus 21 phase 3 trial. British Journal of Haematology, 2021, 192, 1015-1019. | 2.5 | 8 |
| 174 | Molecular remission and non-Hodgkin's lymphoma. Best Practice and Research in Clinical Haematology, 2002, 15, 549-562. | 1.7 | 7 |
| 175 | Intestinal strictures: a new complication of treatment for primary gastrointestinal diffuse large B-cell lymphoma. British Journal of Haematology, 2008, 140, 712-714. | 2.5 | 7 |
| 176 | Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. Expert Review of Molecular Diagnostics, 2015, 15, 287-289. | 3.1 | 7 |
| 177 | A collaborative approach to enabling stratified cancer medicine in the UK. Drug Discovery Today, 2015, 20, 1414-1418. | 6.4 | 7 |
| 178 | RIVA â€“ a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. Trials, 2018, 19, 619. | 1.6 | 7 |
| 179 | Comparative analysis of gene expression platforms for cellâ€ofâ€origin classification of diffuse large Bâ€cell lymphoma shows high concordance. British Journal of Haematology, 2021, 192, 599-604. | 2.5 | 7 |
| 180 | Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Annals of Hematology, 2021, 100, 1049-1058. | 1.8 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244. Blood, 2008, 112, 370-370. | 1.4 | 7 |
| 182 | Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2â€‰+â€‰breast carcinoma. Scientific Reports, 2022, 12, . | 3.3 | 7 |
| 183 | Survival from non-Hodgkin lymphoma in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S107-S109. | 6.4 | 6 |
| 184 | III. Applying molecular phenotyping in practice. Hematological Oncology, 2013, 31, 29-32. | 1.7 | 6 |
| 185 | Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkinâ€™s Lymphoma?. Current Treatment Options in Oncology, 2017, 18, 15. | 3.0 | 6 |
| 186 | Options for first line therapy of Hodgkin lymphoma. Hematological Oncology, 2019, 37, 82-86. | 1.7 | 6 |
| 187 | Current treatment paradigms for advanced stage Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 60-71. | 2.5 | 6 |
| 188 | Progressive multifocal leukoencephalopathy (PML) following autologous peripheral blood stem cell transplantation for multiple myeloma. Clinical Case Reports (discontinued), 2020, 8, 938-943. | 0.5 | 6 |
| 189 | Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204). Blood, 2021, 138, 44-44. | 1.4 | 6 |
| 190 | The therapeutic use of antibodies for malignancy. Transfusion Clinique Et Biologique, 2001, 8, 255-259. | 0.4 | 5 |
| 191 | A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. Chemotherapy, 2012, 58, 257-263. | 1.6 | 5 |
| 192 | Stratified medicine for cancer therapy. Drug Discovery Today, 2012, 17, 261-268. | 6.4 | 5 |
| 193 | Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM)â€“Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin Lymphoma: An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 483-488. | 2.0 | 5 |
| 194 | Lymphoma: turning biology into cures. Clinical Medicine, 2016, 16, s125-s129. | 1.9 | 5 |
| 195 | Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. Haematologica, 2019, 104, e174-e177. | 3.5 | 5 |
| 196 | Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica, 2020, 105, 318-321. | 3.5 | 5 |
| 197 | Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large Bâ€cell lymphoma in the phase III clinical trial of Râ€CHOPÂÂ±Âibrutinib. British Journal of Haematology, 2021, 194, 83-91. | 2.5 | 5 |
| 198 | Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. British Journal of Haematology, 2000, 111, 766-773. | 2.5 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. Blood, 2018, 132, 4097-4097. | 1.4 | 5 |
| 200 | A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010). Blood, 2012, 120, 4850-4850. | 1.4 | 5 |
| 201 | KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. Journal of Immunology, 2022, 209, 379-390. | 0.8 | 5 |
| 202 | Harnessing Innate Immunity to Suppress Lymphoma. Journal of Clinical Oncology, 2010, 28, 4295-4296. | 1.6 | 4 |
| 203 | Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 2018, 3, e000408. | 4.5 | 4 |
| 204 | High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients. Blood, 2019, 134, 1752-1752. | 1.4 | 4 |
| 205 | Utilizing a collaborative working model to optimize molecular analysis of solid tumors in the Cancer Research UK's Stratified Medicine Programme.. Journal of Clinical Oncology, 2013, 31, 11094-11094. | 1.6 | 4 |
| 206 | Risk- and response-adapted strategies for the management of Hodgkin lymphoma. Chinese Clinical Oncology, 2015, 4, 13. | 1.2 | 4 |
| 207 | BAG-1 inhibits PPARÎ³-induced cell death, but not PPARÎ³-induced transcription, cell cycle arrest or differentiation in breast cancer cells. Oncology Reports, 2008, , . | 2.6 | 3 |
| 208 | Expression of inhibitory Fc receptor (FcÎ³RIIB) is a marker of poor response to rituximab monotherapy in follicular lymphoma. Lancet, The, 2013, 381, S63. | 13.7 | 3 |
| 209 | Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S380-S381. | 0.4 | 3 |
| 210 | Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study. Blood, 2020, 136, 38-39. | 1.4 | 3 |
| 211 | Prediction of Response to Recombinant Erythropoietin Plus Granulocyte-Colony Stimulating Factor Following a Single Subcutaneous Bolus in Patients with Myelodysplastic Syndromes; a Randomised Placebo Controlled Study.. Blood, 2004, 104, 1435-1435. | 1.4 | 3 |
| 212 | R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. Blood, 2015, 126, 2689-2689. | 1.4 | 3 |
| 213 | Persistence of clonal Tâ€cell expansions following highâ€dose chemotherapy and autologous peripheral blood progenitor cell rescue. British Journal of Haematology, 2000, 111, 766-773. | 2.5 | 2 |
| 214 | P-356 Addition of SRL172 (Mycobacterium vaccae) to standard chemotherapy in small cell lung cancer (SCLC) confers no survival benefit: Results of a randomised multicentre study. Lung Cancer, 2003, 41, S181-S182. | 2.0 | 2 |
| 215 | Advanced Hodgkin lymphomaâ€"balancing toxicity and cure. Nature Reviews Clinical Oncology, 2011, 8, 634-636. | 27.6 | 2 |
| 216 | Responseâ€adapted therapy in Hodgkin lymphoma. Hematological Oncology, 2017, 35, 33-36. | 1.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 402-402. | 1.4 | 2 |
| 218 | A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial. Blood, 2018, 132, 2956-2956. | 1.4 | 2 |
| 219 | Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Blood, 2020, 136, 16-18. | 1.4 | 2 |
| 220 | Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. Blood, 2012, 120, 1566-1566. | 1.4 | 2 |
| 221 | Emerging findings in the Cancer Research UK stratified medicine program.. Journal of Clinical Oncology, 2012, 30, TPS10633-TPS10633. | 1.6 | 2 |
| 222 | Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour. Blood, 2013, 122, 3013-3013. | 1.4 | 2 |
| 223 | Allele Imbalance at Tumour Suppressor Loci During the Indolent Phase of Follicle Centre Cell Lymphoma. Leukemia and Lymphoma, 1996, 22, 113-117. | 1.3 | 1 |
| 224 | Bone marrow transplants. BMJ: British Medical Journal, 2002, 325, 348-349. | 2.3 | 1 |
| 225 | HD2000 Update in Hodgkin Lymphomaâ€”ABVD or BEACOPP?. Journal of Clinical Oncology, 2016, 34, 3584-3585. | 1.6 | 1 |
| 226 | Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure. Hematological Oncology, 2021, 39, 39-45. | 1.7 | 1 |
| 227 | Primary Mediastinal Large B-Cell Lymphoma. , 2014, , 195-206. | | 1 |
| 228 | Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study. Blood, 2018, 132, 1960-1960. | 1.4 | 1 |
| 229 | Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. Blood, 2006, 108, 2723-2723. | 1.4 | 1 |
| 230 | Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).. Blood, 2009, 114, 3939-3939. | 1.4 | 1 |
| 231 | A national platform for molecular diagnostics: Results of the Cancer Research U.K. Stratified Medicine Programme.. Journal of Clinical Oncology, 2014, 32, 11079-11079. | 1.6 | 1 |
| 232 | Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.. Blood, 2004, 104, 311-311. | 1.4 | 1 |
| 233 | Principles of Chemotherapy in Hodgkin Lymphoma. , 2011, , 141-161. | | 1 |
| 234 | Hdm2 Recruits the Hypoxia Sensitive Transcriptional Co-Repressor CtBP2 to Negatively Regulate p53-Dependant Transcription. Clinical Science, 2003, 104, 29P-29P. | 0.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma. Journal of Clinical Oncology, 2006, 24, 3309-3309. | 1.6 | 0 |
| 236 | Cancer Research UK promotes research in surgery. Bulletin of the Royal College of Surgeons of England, 2009, 91, 194-195. | 0.1 | 0 |
| 237 | A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy. Trials, 2013, 14, . | 1.6 | 0 |
| 238 | Is there a role for consolidation radiotherapy in Hodgkinâ€™s lymphoma in the era of the PET scan?. International Journal of Hematologic Oncology, 2013, 2, 27-38. | 1.6 | 0 |
| 239 | Principles of Chemotherapy in Hodgkin Lymphoma. Hematologic Malignancies, 2015, , 177-199. | 0.2 | 0 |
| 240 | In Reply to Adams and Kwee. International Journal of Radiation Oncology Biology Physics, 2017, 97, 870-871. | 0.8 | 0 |
| 241 | Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approachesâ€”Focus on EZH2-Targeted Drugs. Current Oncology Reports, 2021, 23, 76. | 4.0 | 0 |
| 242 | O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data. Annals of Oncology, 2021, 32, S292. | 1.2 | 0 |
| 243 | Late Events in Patients with Relapsed or Refractory Hodgkinâ€™s Lymphoma Treated with an Autologous Stem Cell Transplantation.. Blood, 2007, 110, 834-834. | 1.4 | 0 |
| 244 | Expression of Inhibitory Fc Receptor (FcÎ³RIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).. Blood, 2012, 120, 2747-2747. | 1.4 | 0 |
| 245 | A â€œUniversalâ€•Lectin-Mediated Interaction Drives B-Cell Receptor Signaling In Primary Follicular Lymphoma Cells. Blood, 2013, 122, 4291-4291. | 1.4 | 0 |
| 246 | Antibody Therapy in Oncology. , 2014, , 101-110. | | 0 |
| 247 | Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy. Blood, 2015, 126, 2663-2663. | 1.4 | 0 |
| 248 | Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425). Blood, 2015, 126, 331-331. | 1.4 | 0 |
| 249 | Abstract B055: Augmentation of OX40-dependent NK mediated antitumor activity is dependent on antibody cross-linking. , 2016, , . | | 0 |
| 250 | Abstract B046: Therapeutic mechanisms of anti-4-1BB antibodies in cancer: agonism versus regulatory T cell depletion. , 2016, , . | | 0 |
| 251 | Abstract CT162: ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL). , 2018, , . | | 0 |
| 252 | Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. Blood, 2019, 134, 2769-2769. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | elearning for cancer immunotherapy. Ecancermedicalscience, 2020, 14, ed94. | 1.1 | 0 |
| 254 | Treatment of Advanced-Stage Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 249-264. | 0.2 | 0 |
| 255 | Interim Cell-Free Circulating Lymphoma DNA Analysis of the Phase 2 Accept Trial. Blood, 2020, 136, 24-25. | 1.4 | 0 |
| 256 | Smart salvage treatment for Hodgkin lymphoma. Blood, 2022, 139, 3563-3564. | 1.4 | 0 |